Arthur Kavanaugh, MD
Kavanaugh A.; Danazol Therapy in Thrombocytopenia Associated with the Antiphospholipid Antibody Syndrome. Ann Intern Med. 1994;121:767-768. doi: 10.7326/0003-4819-121-10-199411150-00007
Download citation file:
Published: Ann Intern Med. 1994;121(10):767-768.
Thrombocytopenia has long been recognized as one of the cardinal manifestations of the antiphospholipid antibody syndrome . In patients with the antiphospholipid antibody syndrome or conditions such as systemic lupus erythematosus, a clear correlation exists between the presence of antiphospholipid antibodies and thrombocytopenia . Although the mechanism of thrombocytopenia in the antiphospholipid antibody syndrome has not been defined, therapy directed specifically toward the thrombocytopenia in this syndrome may be similar to that used in other types of immune thrombocytopenia. Danazol, an attenuated androgen, has proved to be efficacious in the treatment of refractory thrombocytopenia in idiopathic thrombocytopenic purpura [3, 4] and in systemic lupus erythematosus . We describe the successful use of danazol as a steroid-sparing agent for thrombocytopenia in a patient with the antiphospholipid antibody syndrome.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Platelet Disorders.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only